Neuphoria Therapeutics Inc. NEUP 深 沪
交易中 09-22 12:01:48 美东时间
3.73
+0.020
+0.54%
华盛通- 最 高3.73
- 今 开3.72
- 成交量 1091股
- 最 低 3.72
- 昨 收 3.71
- 总市值 2018.43万
- 52周最高 21.4004
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 3.19
- 委 比 49.75%
- 总股本 541.13万
- 历史最高 21.4004
- 量 比 0.17
- 振 幅 0.27%
- 历史最低 2.90
- 每 手 1
- 风险率 3.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Accenture, Abivax and 3 Stocks to Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Abivax SA (NASDAQ:ABVX) to post a first-half loss of $1.08 per share on revenue of $1.86 million after the closing bell, according to data from Ben...
09-21 14:06
Neuphoria Therapeutics Q4 EPS $(0.95) Misses $(0.56) Estimate, Sales $1.174M.
Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.56) by 69.64 percent. This is a 76.13 percent increase over losses of $(3.98) per share from the same period last year. The company reported $1.174 million in sales ...
09-19 05:26
Neuphoria To Be Acquired By Scancell In All-Share Deal; Combined Company To Seek $89M In Private Placement Proceeds And Debt Financing Upon U.S. Listing
Scancell Holdings plc (AIM: SCLP) ("Scancell") and Neuphoria Therapeutics Inc. (NASDAQ:NEUP) ("Neuphoria") today announce an all-share merger in which Scancell will acquire Neuphoria. Upon completion of the Transaction, the combined company plans to operate under the name Scancell and will a...
07-23 18:16
Neuphoria Therapeutics Confirms Discussions With Scancell Holdings About Potential Acquisition; Financial Terms Undisclosed
Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement...
06-27 04:16
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Neuphoria Therapeutics confirms discussions with Scancell Holdings plc regarding a potential acquisition, with Scancell becoming a Nasdaq-listed company post-transaction. The company, focused on neuropsychiatric disorder therapies, is evaluating strategic alternatives. Neuphoria's lead candidate, BNC210, targets PTSD, though development in social anxiety was halted after a failed Phase 3 trial. The company also has early-stage programs for Alzhei...
06-26 20:15
Deal Dispatch: GoPro Retains Houlihan Lokey In Strategic Review, Brookfield Buys World Freight Company, YesCare Corp. Bankruptcy
Major M&A deals this week include: LVMH agrees to sell Marc Jacobs to WHP Global, 365 Markets buys Cantaloupe, Apollo mulls sale of MFIC.
05-16 02:44
HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades Neuphoria Therapeutics (NASDAQ:NEUP) from Buy to Neutral.
05-16 01:34
Neuphoria Therapeutics Q3 EPS $(0.09) Beats $(0.97) Estimate
Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.97) by 90.72 percent. This is a 101.37 percent decrease over earnings of $6.55 per
05-15 21:23
美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
2025-12-08 08:34
